Sarcomas | Specialty

A Genomic Strategy for Each Patient? Sarcomas Are That Complex

July 20th 2016

Researchers are focusing genomic sequencing studies on many different types of sarcomas to emphasize the significant heterogeneity and the unique molecular mechanisms underlying the development of these cancers.

Dr. Federman on Use of Nanotechnology in Sarcomas

July 19th 2016

Noah Federman, MD, director, Pediatric Bone and Soft Tissue Sarcoma Program, University of California, Los Angeles, discusses the use of nanotechnology as a treatment for patients with sarcomas.

Dr. George D. Demetri on the Impact of Sarcoma Subtyping on Other Cancers

July 12th 2016

Aldoxorubicin Misses Primary Endpoint in Phase III Sarcoma Study

July 12th 2016

Treatment with aldoxorubicin failed to improve progression-free survival compared with investigator's choice of therapy for patients with advanced soft tissue sarcoma.

Dr. Jonathan Trent on Engineered T- cell Therapy in Sarcoma

July 9th 2016

Overcoming Challenges With Treating Young Sarcoma Patients

June 21st 2016

Noah Federman, MD, discusses challenges with treating pediatric patients and adolescent and young adults with sarcomas and ongoing efforts to overcome these obstacles.

Sarcoma Expert Shares Excitement Over New Targets and Treatments

June 20th 2016

Brian A. Van Tine, MD, PhD, discusses ongoing research in sarcomas, as well as provides insight on the impact existing drugs are making on the treatment landscape and what community oncologists need to know about this ever-changing field.

Dr. Philip on Treatment Challenges for Patients With Soft Tissue Sarcoma

June 20th 2016

Tony Philip, MD, medical oncologist, Monter Cancer Center of the North Shore-LIJ Cancer Institute, assistant professor of Medicine, Hofstra-North Shore LIJ School of Medicine and NYIT College of Osteopathic Medicine, discusses treatment challenges for patients with soft tissue sarcoma.

Efforts Continue to Advance Targeted and Immunotherapy Agents in Sarcoma

June 20th 2016

Jonathan C. Trent, MD, PhD, discusses notable findings in sarcomas that emerged at the 2016 ASCO Annual Meeting, as well as what lies ahead for the field of sarcomas.

Advances Continue in Sarcoma Care, Offer Blueprint for Other Tumor Types

May 16th 2016

George D. Demetri, MD, discusses current trends in sarcoma care, how the field of sarcoma has paved the way for other tumor types, and emerging therapeutic advances in the field.

Eribulin Gains EU Approval for Advanced Liposarcoma

May 5th 2016

The European Commission has approved eribulin mesylate (Halaven) as a treatment for patients with advanced or unresectable liposarcoma following anthracycline-based chemotherapy.

Anti-Proliferative Activity of Eribulin in Select Sarcoma Cell Lines

May 5th 2016

Junji Matsui, PhD, senior director, Eisai, discusses a preclinical study of eribulin (Halaven) demonstrating anti-proliferative activity in select soft tissue sarcoma cell lines.

FDA Grants Olaratumab Priority Review for Soft Tissue Sarcoma

May 4th 2016

The FDA has granted the PDGFRα antagonist olaratumab a priority review for use in combination with doxorubicin for the treatment of patients with advanced soft tissue sarcoma who are not good candidates for radiotherapy or surgery.

Dr. Demetri on the Evolving Field of Sarcoma

April 27th 2016

George D. Demetri, MD, senior vice president for Experimental Therapeutics at the Dana-Farber Cancer Institute, professor of Medicine at Harvard Medical School, and co-director of the Ludwig Center at Harvard, discusses the evolving and advancing field of sarcoma.

Rare Sarcomas Pose Significant Hurdles, But Foster Collaboration

April 18th 2016

Damon Reed, MD, discusses the challenges associated with treating rare sarcomas, the importance of collaboration, advancements in the field, and the potential for immunotherapy in the disease.

CHMP Recommends Approval of Eribulin for Advanced Liposarcoma

April 5th 2016

Eribulin mesylate (Halaven) has received a positive recommendation from the EMA’s Committee for Medicinal Products for Human Use as a treatment for patients with advanced or unresectable liposarcoma following prior treatment with an anthracycline-based chemotherapy.

The Future of Sarcoma: Nanotechnology, Immunotherapy, and Shark Research

March 29th 2016

H. Thomas Temple, MD, explains where he sees the future of sarcoma going and what diagnostic technologies and therapeutic advancements he is most excited about.

Trabectedin Offers Third-Line Option in Uterine Leiomyosarcoma

March 24th 2016

Martee L. Hensley, MD, discusses what lies ahead for the treatment paradigm of uterine leiomyosarcoma

Eribulin Liposarcoma Approval Advances Precision Medicine in Oncology

March 23rd 2016

George Demetri, MD, discusses the impact of the eribulin’s FDA approval, what oncologists can learn from studying liposarcoma, and the challenges that come with treating a rare disease.

Trabectedin Significantly Slows Progression in Uterine Leiomyosarcoma

March 20th 2016

Treatment with trabectedin significantly improved progression-free survival compared with dacarbazine in women with advanced uterine leiomyosarcoma, according to a subgroup analysis of the phase III SAR-3007 trial.